Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

6794.TW

STRONG SELLREMOVE

UnicoCell Biomed Co., Ltd. · Healthcare · Taiwan · $159M · Avg Vol: $120K/d

18
StockRank
Q
38
V
23
M
43
P/E (TTM)
—
ROE
-13.5%
D/E
0.1x
Dividend %
—
Director Trades · 180d
None in 180d →
Buybacks · 180d
None in 180d →
AI CONVICTION THESIS

UnicoCell Biomed is a speculative biotech company lacking the commercial scale, cash flows, and CDMO pricing power required to justify an investment.

COMPANY DESCRIPTION

UnicoCell Biomed Co., Ltd. develops stem cell therapies and regenerative medicine products, focusing on adipose-derived stem cells (ADSCs). The company possesses proprietary cell processing technologies and a patented cell storage platform to support clinical trials in osteoarthritis and dry eye syndrome. It is a pioneering biotechnology firm in Taiwan's emerging regenerative medicine and cell therapy sector.

FINANCIAL SUMMARY (USD)

Year20212022202320242025CAGR
Revenue—0.5M0.8M1.0M1.0M27.9%
EPS-0.07-0.07-0.05-0.05——
Shares—42.4M55.7M58.4M63.6M+50.2%
Debt—2.1M2.3M2.2M2.0M-2.3%
Equity—10.5M18.8M21.6M27.3M37.4%
Op CF—-2.0M-2.1M-1.9M-2.9M—
Inv CF—-5.2M-9.7M-3.9M-5.5M—
Fin CF—4.8M10.7M5.5M9.4M—
Loading...
PRICE (1Y)-2.7%
2.482.522.552.592.63May 12Jun 2Jun 23
SMA 50SMA 200
Close
$2.50
RSI (14)
25.7
52W High
$3.03
From 52W High
0.8%

SCORE BREAKDOWN

Quality
38
ROIC
-12.3%32.8
ROE
-13.5%33.1
GP/Assets
1.7%13.5
Op. Margin
-422.9%10.4
FCF/Assets
-6.8%32.7
Piotroski
316.1
Int. Cover
-50.0x6.0
D/E Ratio
0.07x70.6
Current Ratio
40.56x99.0
Value
23
P/E (TTM)
—N/A
EV/EBITDA
-39.3x25.0
P/FCF
—N/A
P/B
6.0x21.7
P/S
189.5x5.2
Div Yield
—N/A
Momentum
43
52W High %
82%77.9
RS 6M
-69%15.4
SMA 50/200
1.00x63.8
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
—N/A

FUNDAMENTALS

Market Cap
$159M
P/E (Forward)
—
Gross Margin
61.8%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 6794.TW are excluded.

TickerCompanyMkt CapStockRankSignal
6794.TWUnicoCell Biomed Co., Ltd.(you)$159M18STRONG SELL
4157.TWOTaiGen Biopharmaceuticals Holdings Limited$193M16STRONG SELL
6492.TWOSenhwa Biosciences, Inc.$121M17STRONG SELL
6838.TWFormosa Pharmaceuticals, Inc.$116M15STRONG SELL
3176.TWOMedigen Biotechnology Corp.$146M28SELL
4178.TWStemCyte International, Ltd.$117M12STRONG SELL
4168.TWOGlycoNex Incorporation$91M17STRONG SELL
4726.TWOMycenax Biotech Inc.$160M5STRONG SELL
4142.TWAdimmune Corporation$229M25SELL
6733.TWOBioGend Therapeutics Co., Ltd.$102M12STRONG SELL

Peer medians: ROE 3.6% · P/E 16.2x · Gross margin 42.1%

UnicoCell Biomed Co., Ltd. (6794.TW) — Stock Score Summary

UnicoCell Biomed Co., Ltd. (6794.TW) has a MoatMap StockRank of 18/100 based on Quality (38/100), Value (23/100), and Momentum (43/100) factor scores. The current signal is STRONG SELL. UnicoCell Biomed is a speculative biotech company lacking the commercial scale, cash flows, and CDMO pricing power required to justify an investment.

UnicoCell Biomed Co., Ltd. develops stem cell therapies and regenerative medicine products, focusing on adipose-derived stem cells (ADSCs). The company possesses proprietary cell processing technologies and a patented cell storage platform to support clinical trials in osteoarthritis and dry eye syndrome. It is a pioneering biotechnology firm in Taiwan's emerging regenerative medicine and cell therapy sector.

Key Financial Metrics

Price$2.50
Market Cap$159M
Price/Book5.96
Return on Equity-13.5%
Return on Invested Capital-12.3%
Debt/Equity7.17
Gross Margin61.8%
Operating Margin-422.9%
Revenue Growth-36.2%
Free Cash Flow$-65K

UnicoCell Biomed Co., Ltd. operates in the Biotechnology industry, part of the Healthcare sector (Taiwan).

Frequently Asked Questions

What is UnicoCell Biomed Co., Ltd.’s (6794.TW) StockRank?
MoatMap’s StockRank for UnicoCell Biomed Co., Ltd. (6794.TW) is 18/100, with a Strong Sell signal. It is a composite of Quality (38), Value (23), and Momentum (43) factor ranks across MoatMap’s 20,000+ stock universe.
Does UnicoCell Biomed Co., Ltd. have an economic moat?
UnicoCell Biomed Co., Ltd. (6794.TW) has a Quality factor score of 38/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is UnicoCell Biomed Co., Ltd. a buy, hold, or sell?
MoatMap’s current signal for UnicoCell Biomed Co., Ltd. (6794.TW) is Strong Sell, based on a StockRank of 18/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is UnicoCell Biomed Co., Ltd. in?
UnicoCell Biomed Co., Ltd. (6794.TW) operates in the Healthcare sector, specifically the Biotechnology industry (Taiwan).
Browse all ranked stocks6794.TW deep dive reportAI ChampionsHow we score stocksSense-check another stock